Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response
(2005) In Journal of Viral Hepatitis 12(5). p.473-480- Abstract
- To optimize treatment of chronic hepatitis C early identification of patients who will not achieve a sustained virological response (SVR) is desirable. We investigated hepatitis C virus (HCV) RNA kinetics at day 1 (in 15 patients; genotypes 1 and non-1, 9 and 6 respectively) at weeks 1, 4 and 12 (in 53 patients; genotypes 1 and non-1, 19 and 34, respectively) during treatment with pegylated interferon alpha-2a and ribavirin. Patients with SVR had a significantly more pronounced mean log(10) decline from baseline in HCV RNA levels at weeks 1 and 4 compared with patients who failed to achieve SVR (1.99 vs 0.85 at week 1, P = 0.0003 and 2.89 vs 1.72 at week 4, P = 0.0159), whereas no difference was noted after day 1. For patients with a... (More)
- To optimize treatment of chronic hepatitis C early identification of patients who will not achieve a sustained virological response (SVR) is desirable. We investigated hepatitis C virus (HCV) RNA kinetics at day 1 (in 15 patients; genotypes 1 and non-1, 9 and 6 respectively) at weeks 1, 4 and 12 (in 53 patients; genotypes 1 and non-1, 19 and 34, respectively) during treatment with pegylated interferon alpha-2a and ribavirin. Patients with SVR had a significantly more pronounced mean log(10) decline from baseline in HCV RNA levels at weeks 1 and 4 compared with patients who failed to achieve SVR (1.99 vs 0.85 at week 1, P = 0.0003 and 2.89 vs 1.72 at week 4, P = 0.0159), whereas no difference was noted after day 1. For patients with a 2-log(10) decrease in HCV RNA levels at day 7, the positive predictive value (PPV) for a SVR was 92%, whereas week 12 was the best time point for predicting a later nonresponse [negative predictive value (NPV) 92%] in patients failing to achieve a 2-log(10) drop. For patients with genotype non-1 and a 2-log(10) decrease in HCV RNA levels the PPV for a SVR was 89% week 1, and 79% weeks 4 and 12. The corresponding NPV for patients with genotype non-1 were 43, 40 and 100% respectively. During treatment with pegylated interferon alpha-2a plus ribavirin the HCV RNA decline at week 1 was an accurate predictor of SVR in patients who had achieved a 2-log(10) drop in HCV RNA levels, whereas the lack of such decline week 12 was an accurate marker of a nonresponse. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/227452
- author
- Carlsson, T ; Reichard, O ; Norkrans, G ; Bläckberg, Jonas LU ; Sangfelt, P ; Wallmark, E and Weiland, O
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- ribavirin, sustained virological response, hepatitis C virus RNA, pegylated interferon alpha-2a
- in
- Journal of Viral Hepatitis
- volume
- 12
- issue
- 5
- pages
- 473 - 480
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000231223400004
- pmid:16108761
- scopus:24044531933
- ISSN
- 1365-2893
- DOI
- 10.1111/j.1365-2893.2005.00621.x
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Infection Medicine (SUS) (013008000)
- id
- 2f984a93-f767-42a4-817c-377f08cab2d8 (old id 227452)
- date added to LUP
- 2016-04-01 12:03:44
- date last changed
- 2022-01-26 22:13:01
@article{2f984a93-f767-42a4-817c-377f08cab2d8,
abstract = {{To optimize treatment of chronic hepatitis C early identification of patients who will not achieve a sustained virological response (SVR) is desirable. We investigated hepatitis C virus (HCV) RNA kinetics at day 1 (in 15 patients; genotypes 1 and non-1, 9 and 6 respectively) at weeks 1, 4 and 12 (in 53 patients; genotypes 1 and non-1, 19 and 34, respectively) during treatment with pegylated interferon alpha-2a and ribavirin. Patients with SVR had a significantly more pronounced mean log(10) decline from baseline in HCV RNA levels at weeks 1 and 4 compared with patients who failed to achieve SVR (1.99 vs 0.85 at week 1, P = 0.0003 and 2.89 vs 1.72 at week 4, P = 0.0159), whereas no difference was noted after day 1. For patients with a 2-log(10) decrease in HCV RNA levels at day 7, the positive predictive value (PPV) for a SVR was 92%, whereas week 12 was the best time point for predicting a later nonresponse [negative predictive value (NPV) 92%] in patients failing to achieve a 2-log(10) drop. For patients with genotype non-1 and a 2-log(10) decrease in HCV RNA levels the PPV for a SVR was 89% week 1, and 79% weeks 4 and 12. The corresponding NPV for patients with genotype non-1 were 43, 40 and 100% respectively. During treatment with pegylated interferon alpha-2a plus ribavirin the HCV RNA decline at week 1 was an accurate predictor of SVR in patients who had achieved a 2-log(10) drop in HCV RNA levels, whereas the lack of such decline week 12 was an accurate marker of a nonresponse.}},
author = {{Carlsson, T and Reichard, O and Norkrans, G and Bläckberg, Jonas and Sangfelt, P and Wallmark, E and Weiland, O}},
issn = {{1365-2893}},
keywords = {{ribavirin; sustained virological response; hepatitis C virus RNA; pegylated interferon alpha-2a}},
language = {{eng}},
number = {{5}},
pages = {{473--480}},
publisher = {{Wiley-Blackwell}},
series = {{Journal of Viral Hepatitis}},
title = {{Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response}},
url = {{http://dx.doi.org/10.1111/j.1365-2893.2005.00621.x}},
doi = {{10.1111/j.1365-2893.2005.00621.x}},
volume = {{12}},
year = {{2005}},
}